Personalized Medicine and Genetics: Tailoring Treatment to Your DNA

Pharmacogenomics: Matching Drugs to Genotypes

Pharmacogenomics studies how genetic variation affects drug response, including both therapeutic effectiveness and adverse reactions. Approximately 95 percent of people carry at least one genetic variant that affects their response to commonly prescribed medications. Drug-metabolizing enzymes, drug transporters, and drug targets all vary between individuals due to genetic polymorphisms, creating a spectrum of responses from no effect at standard doses to life-threatening toxicity.

The cytochrome P450 (CYP) enzyme family metabolizes approximately 75 percent of all prescription drugs. Genetic variants in CYP genes create distinct metabolizer phenotypes: poor metabolizers (who break down drugs slowly, leading to accumulation and potential toxicity), normal metabolizers, and ultra-rapid metabolizers (who clear drugs so quickly that standard doses may be ineffective). CYP2D6 alone has over 100 known allelic variants and affects the metabolism of codeine, tamoxifen, many antidepressants, and numerous cardiovascular drugs.

Clinical pharmacogenomic guidelines from organizations like the Clinical Pharmacogenetics Implementation Consortium (CPIC) provide evidence-based prescribing recommendations for over 400 drug-gene pairs. For example, patients with certain CYP2C19 variants should receive alternative antiplatelet therapy instead of clopidogrel (which they cannot activate effectively). Patients with HLA-B*57:01 should never receive abacavir (an HIV drug) because the allele predicts near-certain severe hypersensitivity reaction.

Preemptive pharmacogenomic testing sequences relevant genes before any drug is prescribed, creating a genetic profile that informs all future prescribing decisions throughout the patient lifetime. Several major medical centers now offer preemptive panels testing 10 to 20 pharmacogenes simultaneously, embedding results directly in electronic health records with clinical decision support alerts that fire when a pharmacogenomically-relevant drug is prescribed.

Targeted Cancer Therapy

Cancer genomics has transformed oncology by identifying the specific molecular drivers of each patient tumor, enabling selection of targeted therapies that attack those particular vulnerabilities. Unlike traditional chemotherapy (which kills all rapidly dividing cells indiscriminately), targeted therapies block specific proteins or pathways that the cancer depends on for growth. This precision approach often achieves better outcomes with fewer side effects than conventional treatment.

HER2-positive breast cancers overexpress the HER2 growth factor receptor due to gene amplification. Trastuzumab (Herceptin) specifically blocks HER2 signaling and has transformed outcomes for the approximately 20 percent of breast cancers carrying this alteration. Before genomic testing identified this subtype, HER2-positive cancers had the worst prognosis; with targeted therapy, outcomes have improved dramatically. This example illustrates how molecular characterization can convert a poor-prognosis cancer into a treatable condition.

Non-small cell lung cancers are now routinely tested for mutations in EGFR, ALK fusions, ROS1 rearrangements, BRAF mutations, MET amplifications, RET fusions, and other actionable alterations. Each molecular subtype has specific targeted therapies that produce high response rates in patients carrying that alteration, while being ineffective in patients without it. Comprehensive genomic profiling of tumors through next-generation sequencing panels identifies these targets from a single biopsy, guiding personalized treatment selection.

Tumor mutational burden (TMB) and microsatellite instability (MSI) status predict response to immunotherapy regardless of cancer type. Cancers with high TMB or MSI-high status produce many abnormal proteins (neoantigens) that the immune system can recognize, making them responsive to checkpoint inhibitor immunotherapy. The FDA approval of pembrolizumab for any MSI-high solid tumor (regardless of tissue of origin) represents a landmark in genomics-guided, tissue-agnostic cancer treatment.

Genetic Risk Assessment and Prevention

Genetic testing identifies individuals at elevated risk for specific diseases before symptoms develop, enabling proactive prevention strategies. BRCA1 and BRCA2 mutations increase lifetime breast cancer risk to 45 to 85 percent (versus 12 percent population average) and ovarian cancer risk to 10 to 46 percent. Identified carriers can pursue enhanced surveillance (more frequent mammograms and MRIs), risk-reducing medications (tamoxifen reduces breast cancer risk by approximately 50 percent in carriers), or prophylactic surgery (mastectomy reduces risk by over 90 percent).

Polygenic risk scores (PRS) aggregate the effects of thousands of common genetic variants to estimate an individual risk for complex diseases including coronary heart disease, type 2 diabetes, breast cancer, and Alzheimer disease. While each individual variant has a tiny effect, their combined score can stratify populations into meaningfully different risk categories. Individuals in the top percentiles of polygenic risk for coronary disease have risk equivalent to carrying a single rare high-risk mutation, suggesting they might benefit from earlier and more aggressive preventive interventions.

Cascade testing identifies at-risk family members after a pathogenic variant is found in one individual. When a patient is diagnosed with Lynch syndrome (which increases risk of colorectal, endometrial, and other cancers), genetic testing of first-degree relatives can identify those who inherited the same mutation and need enhanced cancer screening. This approach is highly cost-effective because testing is targeted to a known familial variant rather than requiring comprehensive gene panel analysis for each relative.

Rare Disease Diagnosis

Approximately 350 million people worldwide live with rare diseases, and roughly 80 percent of rare diseases have genetic causes. Many patients endure years-long diagnostic odysseys, seeing numerous specialists and receiving multiple incorrect diagnoses before the underlying genetic cause is identified. Whole-exome and whole-genome sequencing can end these odysseys by identifying causative mutations in a single comprehensive test, even when the clinical presentation does not point to a specific candidate gene.

Studies consistently demonstrate that whole-exome or whole-genome sequencing achieves a diagnostic rate of 25 to 50 percent in previously undiagnosed patients with suspected genetic conditions. The diagnostic yield is highest in children with neurodevelopmental disorders, where early diagnosis can guide management, inform prognosis, connect families with appropriate support resources, and sometimes identify specific treatments that would not otherwise have been considered.

Rapid genome sequencing in neonatal and pediatric intensive care units can provide diagnoses within 24 to 48 hours for critically ill infants, guiding immediate management decisions. Studies have shown that rapid genomic diagnosis changes clinical management in approximately 70 percent of diagnosed cases, including redirecting care toward condition-specific treatments, avoiding ineffective or harmful interventions, and informing decisions about the appropriateness of continued intensive care.

Challenges and Limitations

Genetic literacy among healthcare providers remains a significant barrier to implementing personalized medicine broadly. Many physicians received minimal genetics training during medical school and may lack confidence in ordering genetic tests, interpreting results, or explaining implications to patients. Integration of clinical decision support tools, genetic counselor involvement, and continuing medical education programs are addressing this knowledge gap, but the pace of genomic discovery outstrips most clinicians ability to remain current.

Health disparities in genomic medicine are concerning because most genomic research has been conducted in populations of European descent. Polygenic risk scores developed primarily in European populations perform less accurately in other ancestral groups due to differences in allele frequencies and linkage disequilibrium patterns. Variant interpretation databases also contain more information about variants found in European populations, leading to higher rates of variants of uncertain significance in underrepresented groups. Diversifying research populations is essential for equitable implementation of personalized medicine.

Data interpretation challenges arise from the vast number of genetic variants identified in any individual genome. A typical whole-genome sequence reveals 4 to 5 million variants compared to the reference genome, of which only a handful (if any) are clinically significant. Distinguishing pathogenic variants from benign variation requires extensive databases of variant-phenotype associations, functional characterization studies, and sophisticated computational prediction algorithms, all of which continue to improve but remain imperfect.

Privacy and ethical concerns surround genetic information, which is inherently shared with biological relatives, permanent (the genome does not change), and potentially predictive of future health conditions. Legislation like the Genetic Information Nondiscrimination Act (GINA) provides some protections against discrimination by employers and health insurers, but does not cover life insurance, disability insurance, or long-term care insurance. Patients must understand these limitations when consenting to genetic testing.